CD40LG and myeloid sarcoma: Among 124 serum samples collected from MS patients, 8 (6.5%; 95% CL 3.1–11.8%) for IgM and 17 (13.8%; 95% CL 8.6–20.7%) for IgG were positive, respectively (Fig. 1C,D).